|
|
 |
|
Viewing report
|
|
|
|
Target Analytical Report - ABL1
Jubilant Biosys Limited, Sep 2008, Pages: 158
ABL1 (Abelson murine leukemia viral oncogene homolog 1; c-ABL) belongs to the SRC tyrosine kinase family. ABL1 is involved in many molecular signaling pathways, and plays a role in various cellular processes such as differentiation, DNA repair, stress response, cell division and actin reorganization.
Oncogenic forms of the protein, such as the fusion products BCR-ABL and TEL-ABL, as well as activating mutations in the ABL gene, have been associated with malignant transformation, such as in chronic myelogenous leukemia and a subset of acute lymphoblastic leukemia.
Mutations within the kinase domain of BCR-ABL1 constitute the most frequent mechanism of resistance in patients with chronic myelogenous leukemia treated with imatinib or the second generation tyrosine kinase inhibitors. The malignant potential of this oncoprotein, the drug-resistant mutations and its ability to affect multiple signaling cascades, makes it a desirable therapeutic target.
Today, the drug discovery research sector faces tremendous internal and external pressure due to the huge investments required in terms of money and time in order to produce meaningful information from the huge data sources available in a molecule. This process involves the increased involvement of cross functional domains like those of Molecular Biology, Bioinformatics and Medicinal Chemistry, which has made the process cumbersome and complicated.
The current report on ABL1 addresses the above problem: this report is a compilation of manually curated information that is derived from;
- Public domain databases such as SwissProt, UniProt, Entrez PubMed, OMIM, etc
- In-house databases
- Curated information from journal articles and reviews
- Chemistry information from patents
- Company websites
Competitive Landscape:
The competitive landscape information is obtained by analysis of manually selected patents in the area of small molecules acting on the target.
Customers who bought this item also bought
Drug Target Analytical Report: HCRTR1 - An Insight into Pathways, Disease Associations, Competitive Landscape, Chemotypes, Discovery Pipeline, and Marketed Drugs
Drug Target Analytical Report: HCRTR2 - An Insight into Pathways, Disease Associations, Competitive Landscape, Chemotypes, Discovery Pipeline, and Marketed Drugs
The Drug Target Atlas of Protein Kinase Inhibitors in Oncology
Competitor Analysis: Bcr-Abl and Src Kinase Inhibitors
Gene Therapy - Technologies, Markets and Companies
Acute Lymphoblastic Leukemia or Leukemia or Chronic Lymphocytic Leukemia or Chronic Myelogenous Leukemia or Acute Myelogenous Leukemia or Hairy Cell Leukemia Drug Pipeline Report
Target Analytical Report - CCKBR
Triple Analysis: The Drug Target Atlas of Apoptopic Drugs in Oncology and Special Focus on Lung Cancer and Melanoma
Acute Lymphoblastic Leukemia or Leukemia or Chronic Lymphocytic Leukemia or Chronic Myelogenous Leukemia or Acute Myelogenous Leukemia or Hairy Cell Leukemia Therapy Area Pipeline Report
Protein-Protein Interactions: Are They Now Druggable Targets?
Chronic Myelogenous Leukemia: New Targeted Therapies Take Aim at Gleevec
Cancer Acute Lymphoblastic Leukemia or Leukemia or Chronic Lymphocytic Leukemia or Chronic Myelogenous Leukemia or Acute Myelogenous Leukemia or Hairy Cell Leukemia
|
|
|
|
